Showing 24 out of 106 results
Cyber-ransoms are on the rise: What do you need to know?
‘Cyber-ransoms’ are on the rise, and with new cyber tactics and ways of working, the risks are increasing.KEY TAKEAWAYS A key question facing companies …
ACCC granted first interlocutory injunction to prevent merger in nearly 30 years
For the first time in 27 years, the ACCC has succeeded in obtaining an interlocutory injunction preventing an acquisition from completing until final …
Climate change: succeed in a net-zero future
The risks associated with climate change go way beyond the purely environmental.In our climate change briefing we consider at a high level the political, …
FEDERAL COURT OVERTURNS ‘ABSURD’ PATENT OFFICE RULING ON PATENT TERM EXTENSIONS FOR PHARMACEUTICAL SUBSTANCES
The Federal Court has rejected the Australian Patent Office’s historical approach to patent term extension (PTE) applications, upholding a challenge …
Regulatory reform for software-based consumer health - Can rules keep up with reality?
As Australia moves to liberalise oversight of mobile health apps, we ask if such reforms can keep up with changing technology Mobile health apps and …
Australian Consumer Law marks 10 years with some large penalties
The Australian Consumer Law marked its tenth anniversary on 1 January 2021. Some belated presents were recently delivered in the form of the confirmation …
Pharmaceutical patent term extensions: federal court hears challenge to “absurd” Australian patent office ruling
Two major pharmaceutical companies have challenged Australia’s Commissioner of Patents in the Federal Court about the time limits within which an …
A ‘new normal’ when it comes to the TGA regulation of medical devices?
Key points: In Australia responding to the urgent need for Covid-related medical devices the TGA implemented a number of emergency measures to bring …
Patent and Pharma update, February 2021
Key recent developments in the United Kingdom and Europe relating to patents and the pharmaceutical sector. In this edition we cover an important …
IP in a time of crisis – What does pharma have to do with a low-carbon future?
As crisis stokes calls to water down IP rights, pharma giants have shown pragmatic flexibility. Energy firms using tech to tackle global warming should …
Where is the balance now? Preliminary injunctions in pharmaceutical patent proceedings in 2020 and beyond
Recent decisions of the Federal Court of Australia have significantly changed the way in which parties to pharmaceutical patent litigation should analyse …
Calls for increased domestic pharmaceutical production not warranted, say Herbert Smith Freehills experts
Increased commentary about Australia’s perceived vulnerability to pharmaceutical shortages have led to recent calls for an overhaul of the country’s …
Showing 24 out of 106 results
View more